Introduction {#sec1-0300060519848258}
============

Colorectal cancer is among the most common cancer worldwide and the third most frequent cause of cancer-related mortality. Currently, cancer statistics of Turkey are almost compatible with global data.^[@bibr1-0300060519848258]^ A study from Turkey on colorectal cancer epidemiology with the largest group of patients (n = 968) was published by the Turkish Oncology Group in 2015.^[@bibr2-0300060519848258]^ However, treatment and survival outcomes of these patients were not evaluated in this previous study.

Surgery is the mainstay of treatment of colorectal cancer. However, 5-year disease-free survival (DFS) is unfortunately approximately 49% in stage III cancer, despite recent advances in modern surgical techniques and treatment modalities. The 5-fluorouracil-based chemotherapy regimen has been used for treating high-risk stage II, stage III, and stage IV cases for almost 2 decades.^[@bibr3-0300060519848258]^ Ten years previously, the addition of oxaliplatin to fluorouracil-folinic acid in patients with stage III colon cancer was named the FOLFOX (5-fluorouracil, leucovorin, and oxaliplatin) regimen. This regimen was shown to be advantageous for progression-free survival and overall survival (OS) compared with the regimen without oxaliplatin.^[@bibr4-0300060519848258]^ Subsequently, a combination of capecitabine, which is a fluoropyrimidine analog, and oxaliplatin was used in stage III cancer and was found to be non-inferior to the FOLFOX combination.^[@bibr5-0300060519848258],[@bibr6-0300060519848258]^ Currently, capecitabine and oxaliplatin (CAPOX) and FOLFOX protocols are considered to be equivalent in adjuvant treatment of stage III cases.^[@bibr5-0300060519848258][@bibr6-0300060519848258]--[@bibr7-0300060519848258]^ There has been particular interest in the CAPOX protocol because of the absence of requirement of a vascular port or hospitalization and findings suggesting that CAPOX is more cost-effective compared with the FOLFOX regimen.^[@bibr7-0300060519848258]^ However, no prospective, randomized studies have compared these two protocols in a head-to-head fashion in terms of efficacy, safety, and survival rates.

Therefore, in the present study, we aimed to compare the efficacy, treatment-related side effects, and survival rates of the FOLFOX and CAPOX regimens in patients with stage III colon cancer.

Material and methods {#sec2-0300060519848258}
====================

Data of patients who were followed at the Medical Oncology Units of the hospitals of Mugla Sitki Kocman University and Pamukkale University, and received adjuvant CAPOX and FOLFOX chemotherapy between January 2014 and January 2018 for stage III colon cancer were retrospectively analyzed. Written informed consent was obtained from each patient. The study protocol was approved by the Non-Interventional Research Ethics Board of Pamukkale University (approval date: 04/04/2018; no. 23479). The study was conducted in accordance with the principles of the Declaration of Helsinki.

Inclusion criteria were the presence of stage III colon cancer and receiving the first-line treatment of CAPOX or FOLFOX. Exclusion criteria included metastatic disease at the time of diagnosis, coexisting rectal cancer, and administration of adjuvant chemotherapy in an external center.

Age at the time of diagnosis, Eastern Cooperative Oncology Group performance status, smoking status and alcohol use, comorbidities (including diabetes mellitus, hypertension, and coronary artery disease), prior elective or emergency surgery, localization of the tumor in the colon, T stage according to the American Joint Committee on Cancer classification,^[@bibr8-0300060519848258]^ the number of excised lymph nodes, the number of involved lymph nodes (N stage), chemotherapy protocols selected, the number of previous chemotherapy cycles, time from surgery to chemotherapy, the number of adjuvant chemotherapies, disease progression, OS and progression-free survival rates, and chemotherapy-related side effects as assessed by the Common Terminology Criteria for Adverse Events version 4^[@bibr9-0300060519848258]^ were recorded.

The modified FOLFOX-6 regimen was used in this study. This protocol was composed of intravenous oxaliplatin at a dose of 85 mg/m^2^, intravenous leucovorin infusion at a dose of 400 mg/m^2^, and intravenous bolus 5-fluorouracil and continuous infusion of 5-fluorouracil for 46 hours at a dose of 2400 mg/m^2^ for 12 cycles once every 2 weeks. The CAPOX regimen was composed of intravenous oxaliplatin at a dose of 130 mg/m^2^ on the first day and oral capecitabine at a dose of 1000 mg/m^2^ every 12 hours on Days 1 and 14. This protocol was applied every 21 days for six to eight cycles.

Statistical analysis {#sec3-0300060519848258}
====================

Statistical analysis was performed using the Statistical Package for Social Sciences (SPSS) version 22.0 software (IBM Corp., Armonk, NY, USA). Descriptive data are expressed as mean, median, and percentages. The Student's t-test for continuous variables and Fisher's exact test for categorical variables were used. The Kaplan--Meier method was carried out to evaluate survival of the patients and the log-rank test was used for survival curves. OS and DFS were evaluated using the multivariate Cox proportional hazard model. A p value of ≤ 0.05 was considered statistically significant.

Results {#sec4-0300060519848258}
=======

Of the 243 patients included in the study, 146 (60.1%) were men and 97 (39.9%) were women. The mean age at the time of diagnosis was 61.7 years (range, 32--78 years). Demographic and clinical characteristics of the patients are shown in [Table 1](#table1-0300060519848258){ref-type="table"}.

###### 

Demographic and clinical characteristics of the patients.

![](10.1177_0300060519848258-table1)

                            Number   \%
  ------------------------- -------- ------
  Age (years)                        
   ≤64                      146      60.1
   ≥65                      97       39.9
  Sex                                
   Male                     146      60.1
   Female                   97       39.9
  Smoking                            
   No                       147      60.5
   Ex-smoker                89       36.6
   Smoker                   7        2.9
   Alcohol                           
   No                       231      95.1
   Yes                      12       4.9
  Diabetes mellitus                  
   No                       206      84.8
   Yes                      37       15.2
  Hypertension                       
   No                       129      53.1
   Yes                      114      46.9
  Coronary artery disease            
   No                       231      95.1
   yes                      12       4.9

Histopathological properties of the patients and mutations are presented in [Table 2](#table2-0300060519848258){ref-type="table"}. Only a limited amount of mutation data from patients who had stage III disease at the time of the diagnosis were able to be obtained. This is because mutation analyses of *KRAS*, *NRAS*, and *BRAF* were often evaluated following the development of progression.

###### 

Histopathological properties and mutations of patients.

![](10.1177_0300060519848258-table2)

                            Number   \%
  ------------------------- -------- ------
  Type of operation                  
   Elective                 209      86.0
   Urgent                   34       14.0
  Tumor side                         
   Right                    93       38.3
   Left                     150      61.7
  Differentiation                    
   Good                     16       6.6
   Moderate                 85       35.0
   Poor                     142      58.4
  Lymphovascular invasion            
   No                       76       31.3
   Yes                      167      68.7
  Perineural invasion                
   No                       155      63.8
   Yes                      88       36.2
  *KRAS* mutation                    
   No                       49       40.8
   Yes                      71       59.2
  *NRAS* mutation                    
   No                       47       63.5
   Yes                      27       36.5
  *BRAF* mutation                    
   No                       53       60.9
   Yes                      34       39.1

Among the patients, 106 (43.6%) and 137 (56.4%) were treated with the CAPOX and FOLFOX regimens, respectively. Anthropometric data before chemotherapy according to the regimens are shown in [Table 3](#table3-0300060519848258){ref-type="table"}. Patients who received CAPOX were significantly older than those who received FOLFOX (p = 0.036).

###### 

Anthropometric data before chemotherapy according to the regimens.

![](10.1177_0300060519848258-table3)

                                     Mean ± standard deviation   Median (minimum -- maximum)   P
  ---------------------------------- --------------------------- ----------------------------- -------
  Height (cm)                                                                                  
   CAPOX (n = 106)                   163.73 ± 8.91               164 (136 − 178)               0.142
   FOLFOX (n = 137)                  166.85 ± 9.34               168 (139 − 196)               
  Weight (kg)                                                                                  
   CAPOX (n = 106)                   72.5 ± 12.8                 70.5 (45 − 99)                0.645
   FOLFOX (n = 137)                  73.25 ± 12.36               71.5 (38 − 120)               
  BMI (kg/m^2^)                                                                                
   CAPOX (n=106)                     27.06 ± 4.47                26.75 (17.78 − 43.16)         0.196
   FOLFOX (n = 137)                  26.34 ± 4.14                26.1 (12.87 − 42.02)          
  BSA (m^2^)                                                                                   
   CAPOX (n = 106)                   1.77 ± 0.18                 1.79 (1.32 − 2.1)             0.335
   FOLFOX (n = 137)                  1.79 ± 0.16                 1.8 (1.21 − 2.1)              
  Age (years)                                                                                  
   CAPOX (n = 106)                   63.37 ± 10.15               64 (39 − 83)                  0.036
   FOLFOX (n = 137)                  60.39 ± 9.72                62 (34 − 81)                  
  Operation to chemotherapy (days)                                                             
   CAPOX (n = 106)                   45.6 ± 24.4                 43 (13 − 229)                 0.602
   FOLFOX (n = 137)                  46.46 ± 21.69               44 (15 − 188)                 

CAPOX: capecitabine and oxaliplatin; FOLFOX: 5-fluorouracil, leucovorin, and oxaliplatin; BMI: body mass index; BSA: body surface area.

The effects of genetic mutations, type of surgery, location of involvement of the colon, and the degree of histological differentiation are shown in [Table 4](#table4-0300060519848258){ref-type="table"}. Disease progression was significantly higher in patients with a *KRAS* mutation, an *NRAS* mutation, and moderately/poorly differentiated cases (p = 0.05, p = 0.023, and p = 0.002, respectively). Additionally, an increased number of metastatic lymph nodes and prolonged time from surgery to chemotherapy were significantly associated with disease progression (p = 0.0001 and p = 0.02, respectively).

###### 

Effects of genetic mutations, type of surgery, location of involvement, and the degree of histological differentiation.

![](10.1177_0300060519848258-table4)

                                      Progression                    
  ----------------------------------- --------------- -------------- --------
  *KRAS*                                                             
   Wild                               23 (52.27%)     26 (34.21%)    0.05
   Mutant                             21 (47.73%)     50 (65.79%)    
  *NRAS*                                                             
   Wild                               21 (80.77%)     26 (54.17%)    0.023
   Mutant                             5 (19.23%)      22 (45.83%)    
  *BRAF*                                                             
   Wild                               21 (70%)        32 (56.1%)     0.208
   Mutant                             9 (30%)         25 (43.9%)     
  Operation                                                          
   Elective                           136 (87.18%)    73 (83.91%)    0.481
   Urgent                             20 (12.82%)     14 (16.09%)    
  Tumor side                                                         
   Right                              59 (37.82%)     34 (39.08%)    0.846
   Left                               97 (62.18%)     53 (60.92%)    
  Differentiation                                                    
    Good                              10 (6.41%)      6 (6.9%)       0.002
    Moderate                          67 (42.95%)     18 (20.69%)    
    Poor                              79 (50.64%)     63 (72.41%)    
   Operation to chemotherapy (days)   44.57 ± 23.51   48.8 ± 21.53   0.022
   Total lymph nodes (n)              14.8 ± 5.9      15.9 ± 5.7     0.143
   Metastatic lymph nodes (n)         2.5 ± 3         3.3 ± 2.88     0.0001

Adverse events were evaluated using the Common Terminology Criteria for Adverse Events version 4 v4.03.^[@bibr9-0300060519848258]^ No Grade 4 adverse events were observed in any of the patients. Patients who experienced no adverse events were grouped in one arm and those with Grades 1 to 3 adverse events were grouped in another arm. Adverse events secondary to CAPOX and FOLFOX regimens are shown in [Table 5](#table5-0300060519848258){ref-type="table"}. The frequency of dose reduction of chemotherapy and the rate of treatment discontinuation were higher in the CAPOX arm than in the FOLFOX arm (p = 0.02 and p = 0.007, respectively). Hand-foot syndrome was significantly more common in the CAPOX arm than in the FOLFOX arm (p = 0.008).

###### 

Adverse events secondary to CAPOX and FOLFOX regimens.

![](10.1177_0300060519848258-table5)

                                    Chemotherapy                 
  --------------------------------- -------------- ------------- -------
  Neutropenia                                                    
   No                               54 (50.94)     74 (54.01)    0.634
   Yes                              52 (49.06)     63 (45.99)    
  Thrombocytopenia                                               
   No                               75 (70.75)     104 (75.91)   0.365
   Yes                              31 (29.25)     33 (24.09)    
  Anemia                                                         
   No                               70 (66.04)     100 (72.99)   0.241
   Yes                              36 (33.96)     37 (27.01)    
  Neuropathy                                                     
   No                               72 (67.92)     103 (75.18)   0.211
   Yes                              34 (32.08)     34 (24.82)    
  Hepatotoxicity                                                 
   No                               103 (97.17)    130 (94.89)   0.52
   Yes                              3 (2.83)       7 (5.11)      
  Hand-foot syndrome                                             
   No                               90 (84.91)     130 (94.89)   0.008
   Yes                              16 (15.09)     7 (5.11)      
  Diarrhea                                                       
   No                               58 (54.72)     80 (58.39)    0.566
   Yes                              48 (45.28)     57 (41.61)    
  Dose reduction of chemotherapy                                 
   No                               87 (82.08)     126 (91.97)   0.02
   Yes                              19 (17.92)     11 (8.03)     
  Discontinuation of chemotherapy                                
   No                               95 (89.62)     134 (97.81)   0.007
   Yes                              11 (10.38)     3 (2.19)      

CAPOX: capecitabine and oxaliplatin; FOLFOX: 5-fluorouracil, leucovorin, and oxaliplatin.

The effects of the applied chemotherapy protocols on disease progression, development of metastasis, and the final health condition of patients with stage III colon cancer are shown in [Table 6](#table6-0300060519848258){ref-type="table"}. Disease progression, development of metastasis, and the mortality rate of patients were significantly higher in the FOLFOX arm than in the CAPOX arm (p = 0.016, p = 0.001, p = 0.007, respectively).

###### 

Effects of chemotherapy protocols on disease progression, development of metastasis, and mortality rate.

![](10.1177_0300060519848258-table6)

                 Chemotherapy   P            
  -------------- -------------- ------------ -------
  Progression                                
   No            77 (72.64)     79 (57.66)   0.016
   Yes           29 (27.36)     58 (42.34)   
  Final status                               
   Alive         89 (83.96)     88 (64.23)   0.001
   Dead          17 (16.04)     49 (35.77)   
  Metastasis                                 
   No            78 (73.58)     78 (56.93)   0.007
   Yes           28 (26.42)     59 (43.07)   

CAPOX: capecitabine and oxaliplatin; FOLFOX: 5-fluorouracil, leucovorin, and oxaliplatin.

OS in high-risk patients for disease progression (TNM T4-N2-N3) was significantly shorter compared with that in low-risk patients (TNM T1-T2-T3-N1) (p = 0.006, [Table 7](#table7-0300060519848258){ref-type="table"}). There was no significant difference in OS between the CAPOX and FOLFOX arms ([Figure 1](#fig1-0300060519848258){ref-type="fig"}). Therefore, none of the chemotherapy regimens was superior to another in terms of OS in subgroup analyses.

###### 

Overall survival according to risk groups.

![](10.1177_0300060519848258-table7)

                Alive, n (%)   Dead, n (%)   Mean      Standard deviation   95% CI            P
  ------------- -------------- ------------- --------- -------------------- ----------------- -------
  T4-N2-N3      31 (62)        19 (38)       68.930    6.900                55.410--82.460    0.006
  T1-T2-T3-N1   146 (76)       47 (24)       105.780   4.800                96.360--115.190   

CI: confidence interval.

![Kaplan--Meier overall survival curve according to chemotherapy.](10.1177_0300060519848258-fig1){#fig1-0300060519848258}

Discussion {#sec5-0300060519848258}
==========

Currently, the prognosis of colon cancer is best defined by the American Joint Committee on Cancer classification.^[@bibr8-0300060519848258]^ Consistent with previous findings,^[@bibr8-0300060519848258]^ disease progression was significantly higher in patients with a higher number of metastatic lymph nodes and high-risk patients (T4-N2-N3) in our study. Additionally, we found a negative effect of poor histological differentiation and the presence of *KRAS/NRAS* mutations on disease progression. In the Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) trial, addition of oxaliplatin to fluorouracil and leucovorin increased 5-year progression-free survival from 67.4% to 73.3% and 6-year OS from 76% to 78.5%.^[@bibr4-0300060519848258]^ Increased survival and a decreased mortality rate were achieved with adjuvant chemotherapy in patients with locally advanced (stage III) colon cancer.

An adjuvant treatment alternative in stage III patients is the CAPOX regimen. This regimen consists of intravenous oxaliplatin and capecitabine, which is an oral prodrug. Capecitabine is metabolized in the liver and reduced to 5-fluorouracil. Hospitalization of patients for 48 hours or placement of a subcutaneous vascular port is unnecessary because the CAPOX regimen contains no continuous infusion treatment. In a study by Aitini et al.^[@bibr7-0300060519848258]^, the CAPOX regimen was more cost-effective compared with the FOLFOX regimen, as the adjuvant treatment of colon cancer. Therefore, the CAPOX regimen is primarily preferred in clinical practice. The use of capecitabine was also found to be non-inferior to 5-fluorouracil and folinic acid combination in the X-ACT study.^[@bibr5-0300060519848258]^ Additionally, similar results were obtained with the CAPOX and FOLFOX treatment regimens in the NO169968 study.^[@bibr6-0300060519848258]^ Although both combined chemotherapy regimens appear to have a similar efficacy profile, there has been no head-to-head prospective, randomized study that compared the two protocols in terms of efficacy, safety, and survival rates in the literature.

In a meta-analysis, Des Guetz et al.^[@bibr10-0300060519848258]^ showed that a delayed time from surgery to the initiation of chemotherapy (longer than 8 weeks) decreased the OS rate in patients with stage III colorectal cancer. In the present study, we found no significant difference in the time from surgery to initiation of either chemotherapy regimen, which is inconsistent with previous findings.^[@bibr11-0300060519848258]^ However, when the total patient group was considered, a delay in treatment caused a significant increase in the rate of disease progression.

The CAPOX regimen is preferred in patients with comorbid coronary artery disease. Additionally, the CAPOX regimen is mostly used in young patients,^[@bibr12-0300060519848258]^ although this regimen was used more often in older patients in our study. In our study, the CAPOX regimen was predominantly used in older patients because of existing comorbidities, which may develop secondary to vascular port intervention in this patient population and there is a risk of development of nosocomial infections secondary to hospitalization for fluorouracil infusion treatment. Sara et al.^[@bibr13-0300060519848258]^ also reported an increased incidence of coronary vasospasm, chest pain, angina, and myocardial infarction during fluorouracil bolus and continuous infusion compared with oral capecitabine use. We administered CAPOX in patients who were diagnosed with coronary artery disease to avoid the risk of cardiotoxicity.

The adverse event profile of the CAPOX and FOLFOX regimens is different among previous studies. Mamo et al.^[@bibr14-0300060519848258]^ reported that nausea, diarrhea, neutropenia, and peripheral sensorial neuropathy were more frequent in the FOLFOX arm than in the CAPOX arm. However, Loree et al.^[@bibr15-0300060519848258]^ found that mucositis and neutropenia in the FOLFOX arm and diarrhea and hand-foot syndrome in the CAPOX arm were more frequent. In our study, hand-foot syndrome was significantly more common in the CAPOX arm than in the FOLFOX arm. However, the rate of myelotoxic side effects, such as neutropenia, and other side effects (nausea, diarrhea, mucositis, neuropathy) were similar in both arms.

Loree et al.^[@bibr11-0300060519848258]^ found that DFS was significantly higher in the CAPOX arm than in the FOLFOX arm in their first retrospective study that included 176 patients. These authors also reported a significantly higher DFS with CAPOX in their subsequent study that included 394 patients.^[@bibr15-0300060519848258]^ However, there was no significant difference in the OS rate between the two studies. In our study, development of disease progression, development of metastasis, and the rate of mortality were higher in the FOLFOX arm than in the CAPOX arm. However, we found no significant difference in the OS rate between the CAPOX and FOLFOX arms.

Limitations of the present study include its retrospective nature, short duration of follow-up, and the low rate of expected events.

Conclusion {#sec6-0300060519848258}
==========

In this study, we used a real-life experience to describe baseline characteristics, the operation to chemotherapy interval, toxicity, and effect of FOLFOX and CAPOX on clinical outcomes in patients treated with either FOLFOX or CAPOX in the adjuvant setting in two different institutional practices in the western Anatolia region. The CAPOX regimen was preferred in older patients. Disease progression, metastasis, and the mortality rate were higher in the FOLFOX arm than in the CAPOX arm.
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